The Next Generation Sequencing (NGS) Informatics Market is projected to reach $4.3 billion by 2030, at a CAGR of 15.4% from 2023 to 2030. The demand for NGS informatics tools has increased due to the rising research on novel molecules, growing genomic research projects, and the need for a single informatics platform to query and analyze data at multiple scales. NGS informatics has been widely adopted in clinical and research settings, driven by the emerging needs in precision medicine research and the demand for consolidating and validating data.
Additionally, NGS informatics has been widely adopted for a variety of pharmaceutical applications, such as processing massive volumes of raw sequence information/data into reliable and high-quality data, allowing researchers to store large-scale data, including data processing, and sharing for multi-omics, phenotypic, genomics, and other biomedical data. The NGS informatics platforms have also shown promising results for global collaboration within or across organizations for data exchange while ensuring privacy and security standards.
The growth of the NGS informatics market is driven by increasing R&D investments by pharmaceutical and biotechnology companies, the rising prevalence of cancer and genetic disorders, the growing utilization of NGS in disease diagnostics and precision medicine, technological advancements in NGS informatics solutions, and government initiatives supporting large-scale genomic sequencing projects. However, data confidentiality concerns restrain the growth of this market.
The increasing adoption of NGS informatics tools among hospitals and clinical laboratories and the growing use of bioinformatics and genomic data management solutions for large-scale data analysis and interpretation are expected to create growth opportunities for the players operating in the NGS informatics market. However, the lack of skilled professionals required to operate NGS informatics tools is a major challenge for market growth.
-Informatics-Market.webp "Next Generation Sequencing (NGS) Informatics Market")
Click here to: Get Free Sample Pages of this Report
NGS is widely used for cancer testing and is available in many diagnostic laboratories. Apart from cancer, NGS technologies are also increasingly utilized to diagnose several diseases. NGS can be used to diagnose a wide range of chronic diseases, from novel microbial agents that cause epidemics to heterogeneous mutations that cause complex inherited disorders. NGS is the best option for diagnosing complex diseases involving multiple genes. Autism, connective tissue disorders, cardiomyopathies, and disorders of sex development are a few such diseases. The traditional methods for detecting infectious diseases are time-consuming and sometimes require microbiological cultures. NGS, in contrast, can detect microorganisms directly from samples, including blood and cerebrospinal fluid (CSF). NGS can effectively identify unculturable pathogens that routine culture and sensitivity assays cannot. Furthermore, NGS can also be used to identify pathogens in the early stages of a disease outbreak through genomic sequencing information. The causative factor for drug resistance can also be detected using whole genome sequencing. For instance, mecC is the causative factor for drug resistance in S. aureus infection, and ampC is the causative factor for drug resistance in E. coli infection.
NGS technology has gained significant traction in cancer treatment due to its speed, accuracy, and increasing affordability. It has played a crucial role in developing precision medicine, which involves customizing treatments based on specific molecular changes in a patient's body contributing to the disease. In oncology, NGS is utilized to sequence biopsy samples and identify genetic abnormalities responsible for tumor growth, enabling oncologists to select appropriate targeted therapies. These factors are expected to drive the NGS informatics market, as it becomes essential for managing the vast amount of data associated with disease diagnosis and treatment.
Rising Prevalence of Cancer and Genetic Disorders
NGS is used for sequencing thousands of genes or whole genomes in a short period of time. It is used to detect variants or mutations in a sequence, usually for disease diagnosis, prognosis, clinical decision-making, and management of patients. In the case of genetic disorders and cancer, an individual’s DNA may have several mutations, which are usually detected using NGS. Such mutations have been discovered for many diseases. Whole genome sequencing is more commonly used in clinical settings, mainly for genetic diseases and sometimes for cancer. In the case of rare genetic diseases where no specific mutations have been observed using other molecular tests, NGS is used for whole genome sequencing. According to a review published in the Genome Medicine journal, 300–400 million people worldwide are affected by rare diseases. Also, about 80% of these diseases have genetic causes. According to the United Nations (UN), the global incidence of Down syndrome ranges from 1 in 1,000 to 1 in 1,100 live births. About 3,000 to 5,000 children are born with this chromosome disorder every year.
Cancer has been one of the most complex and expensive diseases globally, with a huge economic burden on many countries. The International Agency for Research on Cancer (IARC) estimates that globally, 1 in 5 people develop cancer during their lifetimes, with 1 in 8 men and 1 in 11 women dying from the disease. Cancer is a major cause of death and a prominent obstacle to improving life expectancy in every country worldwide. According to the International Agency for Research on Cancer (IARC), new cancer cases are expected to increase from 19.2 million in 2020 to 24.5 million by 2030. In addition, mortalities from cancer are expected to increase from 9.9 million in 2020 to 12.9 million by 2030.
NGS is widely used to identify cancer mutations since cancer occurs due to the accumulation of DNA mutations. NGS technologies have been used to identify several novel mutations in various cancers, such as bladder cancer, renal cell carcinoma, small-cell lung cancer, prostate cancer, acute myelogenous leukemia, and chronic lymphocytic leukemia. Furthermore, with the increased prevalence and incidence of cancer, the preference for precision/personalized medicine in oncology is growing, and the need for effective therapies is becoming critical. Precision medicine is being used to treat certain tumors to help determine which tests and treatments are the most effective. It is sometimes used to treat people with certain cancers or people that are at a higher risk of getting specific cancers. Precision medicine for cancer uses the unique genetic makeup of the patient and genetic information from the patient's tumor to discover and determine an appropriate and effective course of treatment. Thus, the increasing prevalence of cancer and genetic disorders is expected to boost the adoption of NGS in clinical and research settings, driving the growth of the NGS informatics market.
Key Players
The report includes a competitive landscape based on an extensive assessment of the key growth strategies adopted by leading market players between 2021 and 2022. The key players profiled in the next generation sequencing (NGS) informatics market report are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Qiagen N.V. (Netherlands), Agilent Technologies, Inc. (U.S.), Sapio Sciences, LLC (U.S.), DNASTAR, Inc. (U.S.), Fabric Genomics, Inc. (U.S.), Partek Incorporated (U.S.), and DNAnexus, Inc. (U.S.).
Based on Offering, the Software Segment is Expected to Account for the Largest Share of the Market
The large market share of this segment is attributed to the benefits provided by NGS software, including data processing and validation, documentation of important news and updates, showcasing projects with special datasets, and the ability to efficiently categorize and analyze data. Additionally, the use of data storage and computing software for various applications, such as post-alignment processing, ensuring variant call accuracy and quality, and facilitating secure and private variant calling for variant identification, drives the growth of this segment.
Based on Application, in 2023, the Drug Discovery Segment is Expected to Account for the Largest Share of the Market
The largest share of this segment is attributed to the decreasing cost of sequencing procedures, increasing R&D by pharmaceutical and biotechnology companies for drug discovery, the increasing applications of NGS in multiple clinical and research settings, and the use of informatics solutions to find pharmacological targets, confirm therapeutic hypotheses, and predict the potential safety of inhibitory compounds aimed at molecular targets.
Based on End User, the Pharmaceutical & Biotechnology Companies Segment is Expected to Account for the Largest Share of the Market
The large market share of this segment is attributed to the declining costs of NGS, the increase in R&D activities among pharmaceutical and biotechnology companies, and the wide usage of NGS informatics solutions by pharmaceutical and biotechnology companies for high-throughput analysis.
Asia-Pacific: Fastest-growing Regional Market
The growth of this regional market is attributed to the accelerated economic growth in many countries within the region, leading to increased government focus on improving the healthcare sector. This has resulted in heightened investments to enhance the accessibility of healthcare services, improve healthcare infrastructure, and support drug discovery programs. Additionally, the rising incidence and prevalence of cancer, the growing adoption of advanced diagnostic and therapeutic technologies, and government initiatives aimed at supporting genome sequencing programs also contribute to the market’s growth in the region.
Scope of the Report:
Next Generation Sequencing (NGS) Informatics Market Assessment, by Offering
Next Generation Sequencing (NGS) Informatics Market Assessment, by Application
Next Generation Sequencing (NGS) Informatics Market Assessment, by End User
Next Generation Sequencing (NGS) Informatics Market Assessment, by Geography
Key questions answered in the report:
This study offers a detailed assessment of the Next Generation Sequencing (NGS) Informatics market and analyzes the market sizes & forecasts based on offering, application, and end user. This report also involves the value analysis of various segments and subsegments of the next generation sequencing (NGS) informatics market at the regional and country levels.
The next generation sequencing (NGS) informatics market is projected to reach $4.3 billion by 2030, at a CAGR of 15.4% during the forecast period.
The software segment is expected to account for the largest share of the market in 2023.
The drug discovery segment is expected to hold the largest share of the market in 2023. The large market share of this segment is attributed to the increasing applications of NGS in various clinical and research areas, the rise in global pharmaceutical research and development activities, and the growing need for data management, analysis, and storage in drug discovery.
The growth of the NGS informatics market is driven by increasing R&D investments by pharmaceutical and biotechnology companies, the rising prevalence of cancer and genetic disorders, the growing utilization of NGS in disease diagnostics and precision medicine, technological advancements in NGS informatics solutions, and government initiatives supporting large-scale genomic sequencing projects.
The key players profiled in the next generation sequencing (NGS) informatics market study are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Qiagen N.V. (Netherlands), Agilent Technologies, Inc. (U.S.), Sapio Sciences, LLC (U.S.), DNASTAR, Inc. (U.S.), Fabric Genomics, Inc. (U.S.), Partek Incorporated (U.S.), and DNAnexus, Inc. (U.S.).
Emerging economies such as China and India are projected to offer significant growth opportunities to the market players due to rising investments in the healthcare sector and increasing genomic projects in these countries.
This report provides pre & post COVID-19 market estimates.
1. Introduction
1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency and Limitation
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Approach
2.2. Process of Data Collection and Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders of The Industry
2.3. Market Sizing and forecast
2.3.1. Market Size Estimation Approach
2.3.2. Growth Forecast Approach
2.3.3. Market Share Analysis
2.4. Assumptions for the Study
3. Executive Summary
4. Market Insights
4.1. Overview
4.2. Factors Affecting Market Growth
4.2.1. Impact Analysis of Market Dynamics
4.2.2. Factor Analysis
4.3. Use Cases
4.3.1. Use Case A
4.3.2. Use Case B
4.3.3. Use Case C
4.3.4. Use Case D
4.3.5. Use Case E
4.4. Porter’s Five Forces Analysis
4.4.1. Bargaining Power of Buyers
4.4.2. Bargaining Power of Suppliers
4.4.3. Threat of Substitutes
4.4.4. Threat of New Entrants
4.4.5. Degree of Competition
4.5. Next–Generation Sequencing (NGS) Informatics Market: Regulatory Analysis
5. Next Generation Sequencing (NGS) Informatics Market Assessment–by Offering
5.1. Overview
5.2. Software
5.2.1. By Type
5.2.1.1. Data Analysis Software
5.2.1.2. Data Interpretation and Reporting Tools
5.2.1.3. Data Storage and Computing Tools
5.2.1.4. Laboratory Information Management Systems (LIMS)
5.2.2. By Deployment Mode
5.2.2.1. Web and Cloud–Based
5.2.2.2. On-Premise
5.3. NGS Informatics Services
6. Next–Generation Sequencing (NGS) Informatics Market Assessment–by Application
6.1. Overview
6.2. Drug Discovery
6.3. Disease Diagnoses
6.4. Biomarker Discovery
6.5. Precision Medicine
6.6. Agriculture and Animal Research
7. Next–Generation Sequencing (NGS) Informatics Market Assessment–by End User
7.1. Overview
7.2. Pharmaceutical & Biotechnology Companies
7.3. Hospitals & Diagnostic Laboratories
7.4. Academic & Research Institutes
7.5. Other End Users
8. Next–Generation Sequencing Informatics (NGS) Market Assessment—by Geography
8.1. Overview
8.2. North America
8.2.1. U.S.
8.2.2. Canada
8.3. Europe
8.3.1. Germany
8.3.2. France
8.3.3. U.K.
8.3.4. Italy
8.3.5. Spain
8.3.6. Rest of Europe (RoE)
8.4. Asia–Pacific
8.4.1. China
8.4.2. Japan
8.4.3. India
8.4.4. Rest of Asia–Pacific (RoAPAC)
8.5. Latin America
8.5.1. Brazil
8.5.2. Mexico
8.5.3. Rest of Latin America
8.6. Middle East & Africa
9. Competition Analysis
9.1. Overview
9.2. Key Growth Strategies
9.3. Competitive Benchmarking
9.4. Market Share Analysis (2022)
9.4.1. Illumina, Inc. (U.S.)
9.4.2. Qiagen N.V. (Netherlands)
9.4.3. Thermo Fisher Scientific Inc. (U.S.)
9.4.4. Agilent Technologies, Inc. (U.S.)
9.4.5. F. Hoffmann–La Roche Ltd (Switzerland)
9.5. Vendor Dashboard
9.5.1. Industry Leaders
9.5.2. Market Differentiators
9.5.3. Vanguards
9.5.4. Emerging Companies
10. Company Profiles (Business Overview, Financial Overview, Product Portfolio, SWOT Analysis of Top 5 Companies, and Strategic Developments)
10.1. Thermo Fisher Scientific, Inc.
10.2. Illumina, Inc.
10.3. QIAGEN N.V.
10.4. F. Hoffmann–La Roche Ltd
10.5. Agilent Technologies, Inc.
10.6. DNAnexus, Inc.
10.7. Partek Incorporated
10.8. Fabric Genomics, Inc.
10.9. DNASTAR, Inc.
10.10. Sapio Sciences, LLC
11. Appendix
11.1. Available Customization
11.2. Related Reports
List of Tables
Table 1 Global NGS Informatics Market: Impact Analysis of Market Dynamics (2023–2030)
Table 2 Estimated Number of New Cancer Cases, by Type (2020 VS. 2030)
Table 3 Common Genetic Disorders: Rates of Occurrence
Table 4 NGS Informatics: Standards and Compliance Guidelines
Table 5 Global NGS Informatics Market, by Offering, 2021–2030 (USD Million)
Table 6 Global NGS Informatics Software Market, by Type, 2021–2030 (USD Million)
Table 7 Global NGS Informatics Software Market, by Country/Region, 2021–2030 (USD Million)
Table 8 Global NGS Data Analysis Software Market, by Country/Region, 2021–2030 (USD Million)
Table 9 Global NGS Data Interpretation and Reporting Tools Market, by Country/Region, 2021–2030 (USD Million)
Table 10 Global NGS Data Storage and Computing Tools Market, by Country/Region, 2021–2030 (USD Million)
Table 11 Global NGS Laboratory Information Management Systems (LIMS) Market by Country/Region, 2021–2030 (USD Million)
Table 12 Global NGS Informatics Software Market, by Deployment Mode, 2021–2030 (USD Million)
Table 13 Global Web and Cloud–Based NGS Informatics Software Market, by Country/Region, 2021–2030 (USD Million)
Table 14 Global On-premise NGS Informatics Software Market, by Country/Region, 2021–2030 (USD Million)
Table 15 Global NGS Informatics Services Market, by Country/Region, 2021–2030 (USD Million)
Table 16 Global NGS Informatics Market, by Application, 2021–2030 (USD Million)
Table 17 Global NGS Informatics Market for Drug Discovery, by Country/Region, 2021–2030 (USD Million)
Table 18 Global NGS Informatics Market for Disease Diagnoses, by Country/Region, 2021–2030 (USD Million)
Table 19 Currently Available Targeted Therapies and Corresponding Biomarkers
Table 20 Global NGS Informatics Market for Biomarker Discovery, by Country/Region, 2021–2030 (USD Million)
Table 21 Global NGS Informatics Market for Precision Medicine, by Country/Region, 2021–2030 (USD Million)
Table 22 Global NGS Informatics Market for Agriculture & Animal Research, by Country/Region, 2021–2030 (USD Million)
Table 23 Global NGS Informatics Market, by End User, 2021–2030 (USD Million)
Table 24 Global NGS Informatics Market for Pharmaceutical & Biotechnology Companies, by Country/Region, 2021–2030 (USD Million)
Table 25 Global NGS Informatics Market for Hospitals & Diagnostic Laboratories, by Country/Region, 2021–2030 (USD Million)
Table 26 Global NGS Informatics Market for Academic & Research Institutes, by Country/Region, 2021–2030 (USD Million)
Table 27 Global NGS Informatics Market for Other End Users, by Country/Region, 2021–2030 (USD Million)
Table 28 Global NGS Informatics Market, by Country/Region, 2021–2030 (USD Million)
Table 29 North America: NGS Informatics Market, by Country, 2021–2030 (USD Million)
Table 30 North America: NGS Informatics Market, by Offering , 2021–2030 (USD Million)
Table 31 North America: NGS Informatics Software Market, by Type, 2021–2030 (USD Million)
Table 32 North America: NGS Informatics Software Market, by Deployment Mode, 2021–2030 (USD Million)
Table 33 North America: NGS Informatics Market, by Application, 2021–2030 (USD Million)
Table 34 North America: NGS Informatics Market, by End User, 2021–2030 (USD Million)
Table 35 U.S.: Key Macro & Microindicators
Table 36 U.S.: NGS Informatics Market, by Offering , 2021–2030 (USD Million)
Table 37 U.S.: NGS Informatics Software Market, by Type, 2021–2030 (USD Million)
Table 38 U.S.: NGS Informatics Software Market, by Deployment Mode, 2021–2030 (USD Million)
Table 39 U.S.: NGS Informatics Market, by Application, 2021–2030 (USD Million)
Table 40 U.S.: NGS Informatics Market, by End User, 2021–2030 (USD Million)
Table 41 Canada: Key Macro & Micro Indicators
Table 42 Canada: NGS Informatics Market, by Offering , 2021–2030 (USD Million)
Table 43 Canada: NGS Informatics Software Market, by Type, 2021–2030 (USD Million)
Table 44 Canada: NGS Informatics Software Market, by Deployment Mode, 2021–2030 (USD Million)
Table 45 Canada: NGS Informatics Market, by Application, 2021–2030 (USD Million)
Table 46 Canada: NGS Informatics Market, by End User, 2021–2030 (USD Million)
Table 47 Europe: NGS Informatics Market, by Country, 2021–2030 (USD Million)
Table 48 Europe: NGS Informatics Market, by Offering , 2021–2030 (USD Million)
Table 49 Europe: NGS Informatics Software Market, by Type, 2021–2030 (USD Million)
Table 50 Europe: NGS Informatics Software Market, by Deployment Mode, 2021–2030 (USD Million)
Table 51 Europe: NGS Informatics Market, by Application, 2021–2030 (USD Million)
Table 52 Europe: NGS Informatics Market, by End User, 2021–2030 (USD Million)
Table 53 Germany: Key Macro & Micro Indicators
Table 54 Germany: NGS Informatics Market, by Offering , 2021–2030 (USD Million)
Table 55 Germany: NGS Informatics Software Market, by Type, 2021–2030 (USD Million)
Table 56 Germany: NGS Informatics Software Market, by Deployment Mode, 2021–2030 (USD Million)
Table 57 Germany: NGS Informatics Market, by Application, 2021–2030 (USD Million)
Table 58 Germany: NGS Informatics Market, by End User, 2021–2030 (USD Million)
Table 59 France: Key Macro & Indicators
Table 60 France: NGS Informatics Market, by Offering , 2021–2030 (USD Million)
Table 61 France: NGS Informatics Software Market, by Type, 2021–2030 (USD Million)
Table 62 France: NGS Informatics Software Market, by Deployment Mode, 2021–2030 (USD Million)
Table 63 France: NGS Informatics Market, by Application, 2021–2030 (USD Million)
Table 64 France: NGS Informatics Market, by End User, 2021–2030 (USD Million)
Table 65 U.K.: Key Macro & Micro Indicators
Table 66 U.K.: NGS Informatics Market, by Offering , 2021–2030 (USD Million)
Table 67 U.K.: NGS Informatics Software Market, by Type, 2021–2030 (USD Million)
Table 68 U.K.: NGS Informatics Software Market, by Deployment Mode, 2021–2030 (USD Million)
Table 69 U.K.: NGS Informatics Market, by Application, 2021–2030 (USD Million)
Table 70 U.K.: NGS Informatics Market, by End User, 2021–2030 (USD Million)
Table 71 Italy: Key Macro & Micro Indicators
Table 72 Italy: NGS Informatics Market, by Offering , 2021–2030 (USD Million)
Table 73 Italy: NGS Informatics Software Market, by Type, 2021–2030 (USD Million)
Table 74 Italy: NGS Informatics Software Market, by Deployment Mode, 2021–2030 (USD Million)
Table 75 Italy: NGS Informatics Market, by Application, 2021–2030 (USD Million)
Table 76 Italy: NGS Informatics Market, by End User, 2021–2030 (USD Million)
Table 77 Spain: Key Macro & Micro Indicators
Table 78 Spain: NGS Informatics Market, by Offering , 2021–2030 (USD Million)
Table 79 Spain: NGS Informatics Software Market, by Type, 2021–2030 (USD Million)
Table 80 Spain: NGS Informatics Software Market, by Deployment Mode, 2021–2030 (USD Million)
Table 81 Spain: NGS Informatics Market, by Application, 2021–2030 (USD Million)
Table 82 Spain: NGS Informatics Market, by End User, 2021–2030 (USD Million)
Table 83 Estimated Number of New Cancer Cases, by Country, 2020 VS. 2030
Table 84 Rest of Europe: NGS Informatics Market, by Offering , 2021–2030 (USD Million)
Table 85 Rest of Europe: NGS Informatics Software Market, by Type, 2021–2030 (USD Million)
Table 86 Rest of Europe: NGS Informatics Software Market, by Deployment Mode, 2021–2030 (USD Million)
Table 87 Rest of Europe: NGS Informatics Market, by Application, 2021–2030 (USD Million)
Table 88 Rest of Europe: NGS Informatics Market, by End User, 2021–2030 (USD Million)
Table 89 Asia–Pacific: NGS Informatics Market, by Country/Region, 2021–2030 (USD Million)
Table 90 Asia–Pacific: NGS Informatics Market, by Offering , 2021–2030 (USD Million)
Table 91 Asia–Pacific: NGS Informatics Software Market, by Type, 2021–2030 (USD Million)
Table 92 Asia–Pacific: NGS Informatics Software Market, by Deployment Mode, 2021–2030 (USD Million)
Table 93 Asia–Pacific: NGS Informatics Market, by Application, 2021–2030 (USD Million)
Table 94 Asia–Pacific: NGS Informatics Market, by End User, 2021–2030 (USD Million)
Table 95 China: Key Macro & Micro Indicators
Table 96 China: NGS Informatics Market, by Offering , 2021–2030 (USD Million)
Table 97 China: NGS Informatics Software Market, by Type, 2021–2030 (USD Million)
Table 98 China: NGS Informatics Software Market, by Deployment Mode, 2021–2030 (USD Million)
Table 99 China: NGS Informatics Market, by Application, 2021–2030 (USD Million)
Table 100 China: NGS Informatics Market, by End User, 2021–2030 (USD Million)
Table 101 Japan: Key Macro & Micro Indicators
Table 102 Japan: NGS Informatics Market, by Offering, 2021–2030 (USD Million)
Table 103 Japan: NGS Informatics Software Market, by Type, 2021–2030 (USD Million)
Table 104 Japan: NGS Informatics Software Market, by Deployment Mode, 2021–2030 (USD Million)
Table 105 Japan: NGS Informatics Market, by Application, 2021–2030 (USD Million)
Table 106 Japan: NGS Informatics Market, by End User, 2021–2030 (USD Million)
Table 107 India: Key Macro & Micro Indicators
Table 108 India: NGS Informatics Market, by Offering , 2021–2030 (USD Million)
Table 109 India: NGS Informatics Software Market, by Type, 2021–2030 (USD Million)
Table 110 India: NGS Informatics Software Market, by Deployment Mode, 2021–2030 (USD Million)
Table 111 India: NGS Informatics Market, by Application, 2021–2030 (USD Million)
Table 112 India: NGS Informatics Market, by End User, 2021–2030 (USD Million)
Table 113 Estimated Number of New Cancer Cases, by Country, 2020 VS. 2030
Table 114 Rest of Asia–Pacific: NGS Informatics Market, by Offering , 2021–2030 (USD Million)
Table 115 Rest of Asia–Pacific: NGS Informatics Software Market, by Type, 2021–2030 (USD Million)
Table 116 Rest of Asia–Pacific: NGS Informatics Software Market, by Deployment Mode, 2021–2030 (USD Million)
Table 117 Rest of Asia–Pacific: NGS Informatics Market, by Application, 2021–2030 (USD Million)
Table 118 Rest of Asia–Pacific: NGS Informatics Market, by End User, 2021–2030 (USD Million)
Table 119 Latin America: NGS Informatics Market, by Country/Region, 2021–2030 (USD Million)
Table 120 Latin America: NGS Informatics Market, by Offering , 2021–2030 (USD Million)
Table 121 Latin America: NGS Informatics Software Market, by Type, 2021–2030 (USD Million)
Table 122 Latin America: NGS Informatics Software Market, by Deployment Mode, 2021–2030 (USD Million)
Table 123 Latin America: NGS Informatics Market, by Application, 2021–2030 (USD Million)
Table 124 Latin America: NGS Informatics Market, by End User, 2021–2030 (USD Million)
Table 125 Brazil: Key Macro & Micro Indicators
Table 126 Brazil: NGS Informatics Market, by Offering , 2021–2030 (USD Million)
Table 127 Brazil: NGS Informatics Software Market, by Type, 2021–2030 (USD Million)
Table 128 Brazil: NGS Informatics Software Market, by Deployment Mode, 2021–2030 (USD Million)
Table 129 Brazil: NGS Informatics Market, by Application, 2021–2030 (USD Million)
Table 130 Brazil: NGS Informatics Market, by End User, 2021–2030 (USD Million)
Table 131 Mexico: Key Macro & Micro Indicators
Table 132 Mexico: NGS Informatics Market, by Offering , 2021–2030 (USD Million)
Table 133 Mexico: NGS Informatics Software Market, by Type, 2021–2030 (USD Million)
Table 134 Mexico: NGS Informatics Software Market, by Deployment Mode, 2021–2030 (USD Million)
Table 135 Mexico: NGS Informatics Market, by Application, 2021–2030 (USD Million)
Table 136 Mexico: NGS Informatics Market, by End User, 2021–2030 (USD Million)
Table 137 Rest of Latin America: NGS Informatics Market, by Offering , 2021–2030 (USD Million)
Table 138 Rest of Latin America: NGS Informatics Software Market, by Type, 2021–2030 (USD Million)
Table 139 Rest of Latin America: NGS Informatics Software Market, by Deployment Mode, 2021–2030 (USD Million)
Table 140 Rest of Latin America: NGS Informatics Market, by Application, 2021–2030 (USD Million)
Table 141 Rest of Latin America: NGS Informatics Market, by End User, 2021–2030 (USD Million)
Table 142 Middle East & Africa: NGS Informatics Market, by Offering , 2021–2030 (USD Million)
Table 143 Middle East & Africa: NGS Informatics Software Market, by Type, 2021–2030 (USD Million)
Table 144 Middle East & Africa: NGS Informatics Software Market, by Deployment Mode, 2021–2030 (USD Million)
Table 145 Middle East & Africa: NGS Informatics Market, by Application, 2021–2030 (USD Million)
Table 146 Middle East & Africa: NGS Informatics Market, by End User, 2021–2030 (USD Million)
Table 147 Recent Developments, by Company, 2020–2023
List of Figures
Figure 1 Research Process
Figure 2 Secondary Sources Referenced for This Study
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply–Side & Demand–Side)
Figure 6 Market Sizing and Growth Forecast Approach
Figure 7 Global NGS Informatics Market, by Offering , 2023 VS. 2030 (USD Million)
Figure 8 Global NGS Informatics Software Market, by Deployment Mode, 2023 VS. 2030 (USD Million)
Figure 9 Global NGS Informatics Market, by Application, 2023 VS. 2030 (USD Million)
Figure 10 Global NGS Informatics Market, by End User, 2023 VS. 2030 (USD Million)
Figure 11 Global NGS Informatics Market Shares, by Geography, 2023
Figure 12 Pharmaceutical R&D Expenditures in the U.S., Europe, and China, 2010 VS. 2019 VS. 2020 (USD Million)
Figure 13 Global Pharmaceutical R&D Expenditure, 2012–2026 (USD Billion)
Figure 14 Porter's Five Forces Analysis
Figure 15 Global NGS Informatics Market, by offering , 2023 VS. 2030 (USD Million)
Figure 16 Global NGS Informatics Software Market, by Deployment Mode, 2023 VS. 2030 (USD Million)
Figure 17 Global NGS Informatics Market, by Application, 2023 VS. 2030 (USD Million)
Figure 18 Estimated Number of New Cancer Cases (In Million)
Figure 19 Percentage of FDA Approvals for Personalized Medicine, 2015–2021
Figure 20 Global NGS Informatics Market, by End User, 2023 VS. 2030 (USD Million)
Figure 21 Global Pharmaceutical R&D Spending, 2014–2028 (USD Billion)
Figure 22 Global NGS Informatics Market, by Geography, 2023 VS. 2030 (USD Million)
Figure 23 North America: NGS Informatics Market Snapshot
Figure 24 U.S.: Pharmaceutical R&D Expenditure, 2014–2021 (USD Billion)
Figure 25 Europe: Pharmaceutical Industry R&D Expenditure (2000–2021)
Figure 26 Europe: NGS Informatics Market Snapshot
Figure 27 Italy: Number of Biotechnology Firms, 2010–2021
Figure 28 RoE: Pharmaceutical R&D Expenditure, 2020
Figure 29 Asia–Pacific: NGS Informatics Market Snapshot
Figure 30 Latin America: NGS Informatics Market Snapshot
Figure 31 Key Growth Strategies Adopted by Leading Players (2020–2023)
Figure 32 Next Generation Sequencing (NGS) Informatics Market: Competitive Benchmarking, by Offering
Figure 33 Next Generation Sequencing (NGS) Informatics Market: Competitive Benchmarking, by Region
Figure 34 Global Next Generation Sequencing (NGS) Informatics Market Share Analysis, by Key Players, 2022 (%)
Figure 35 Vendor Dashboard: Next Generation Sequencing (NGS) Informatics Market
Figure 36 Thermo Fisher Scientific, Inc.: Financial Overview (2022)
Figure 37 Illumina, Inc.: Financial Overview (2022)
Figure 38 QIAGEN N.V.: Financial Overview (2022)
Figure 39 F. Hoffmann–La Roche Ltd: Financial Overview (2022)
Figure 40 Agilent Technologies, Inc.: Financial Overview (2022)
This report provides pre & post COVID-19 market estimates.
This report provides pre & post COVID-19 market estimates.
Published Date: Aug-2023
Published Date: Jan-2023
Published Date: Jun-2022
